Skip to main content
Top
Published in: Tumor Biology 6/2015

01-06-2015 | Review

New approaches for cancer immunotherapy

Authors: Ayfer Karlitepe, Ozgun Ozalp, Cigir Biray Avci

Published in: Tumor Biology | Issue 6/2015

Login to get access

Abstract

Immunotherapy is a promising field that offers alternative methods for treatment of cancer. The current strategy consists of cancer vaccines, monoclonal antibodies, and cellular therapies. Cancer vaccines aim to eradicate cancer cells via immune system. Thus, they may attack these cells derived from any type of cancer, besides their role in preventing cancer. Lymphocytes and dendritic cells are often used in cellular therapy. In addition, monoclonal antibodies are designed to target specific antigens found in cancer cells. Currently, at least 12 clinically approved monoclonal antibodies are being used and many cancer vaccines are being developed with ongoing phase studies for cancer therapy. Relevant studies are focused on glioma and several other cancer types. Correspondingly, the combination of effective methods may enhance the efficacy of immunotherapy. It is thought that particularly immune checkpoint inhibitors will play a crucial role in immunotherapeutic approaches.
Literature
1.
go back to reference Strebhardt K, Ullrich A. Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat Rev Cancer. 2008;8(6):473–80. Strebhardt K, Ullrich A. Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat Rev Cancer. 2008;8(6):473–80.
2.
go back to reference Çağrı Ş, Halit C, Kenan İ. Kanser İmmün Terapi ve MonoklonalAntikorlar. Fırat Üniv Sağlık Bilimleri Tıp Derg. 2013;27(2):105–10. Çağrı Ş, Halit C, Kenan İ. Kanser İmmün Terapi ve MonoklonalAntikorlar. Fırat Üniv Sağlık Bilimleri Tıp Derg. 2013;27(2):105–10.
3.
4.
go back to reference Andrea S, Hans S, Mary P. Specificity in cancer immunotherapy. Semin Immunol. 2008;20(5):276–85.CrossRef Andrea S, Hans S, Mary P. Specificity in cancer immunotherapy. Semin Immunol. 2008;20(5):276–85.CrossRef
5.
go back to reference Rini B. Future approaches in immunotherapy. Semin Immunol. 2014;5:30–40. Rini B. Future approaches in immunotherapy. Semin Immunol. 2014;5:30–40.
7.
go back to reference Harris TJ, Drake CG. Primer on tumor immunology and cancer immunotherapy. J Immunother Cancer. 2013;1:12. Harris TJ, Drake CG. Primer on tumor immunology and cancer immunotherapy. J Immunother Cancer. 2013;1:12.
8.
go back to reference Akiko K, Akira I, Chie O, Ken Y, Koichi M, Masaru K, et al. Anti-vascular endothelial growth factor receptor (VEGFR) 2 autoantibody identification in glioblastoma patient using single B cell-based antibody gene cloning. Immunol Lett. 2014;159:15–22.CrossRef Akiko K, Akira I, Chie O, Ken Y, Koichi M, Masaru K, et al. Anti-vascular endothelial growth factor receptor (VEGFR) 2 autoantibody identification in glioblastoma patient using single B cell-based antibody gene cloning. Immunol Lett. 2014;159:15–22.CrossRef
9.
go back to reference Hiroaki W, Jianfang N, Samuel D. Immunovirotherapy for glioblastoma. Cell Cycle. 2014;13(2):175–6.CrossRef Hiroaki W, Jianfang N, Samuel D. Immunovirotherapy for glioblastoma. Cell Cycle. 2014;13(2):175–6.CrossRef
10.
go back to reference Ming X, Ping Z, Wei H, Yu Y, Zhebao W. Mouse glioma immunotherapy mediated by A2B5+ GL261 cell lysate-pulsed dendritic cells. J Neuro-Oncol. 2014;116:497–504.CrossRef Ming X, Ping Z, Wei H, Yu Y, Zhebao W. Mouse glioma immunotherapy mediated by A2B5+ GL261 cell lysate-pulsed dendritic cells. J Neuro-Oncol. 2014;116:497–504.CrossRef
11.
go back to reference Thaci B, Ahmed AU, Ulasov IV, Wainwright DA, Nigam P, Auffinger B, Tobias AL, Han Y, Zhang L, Moon KS, Lesniak MS. Depletion of myeloid-derived suppressor cells during interleukin-12 immunogene therapy does not confer a survival advantage in experimental malignant glioma. Cancer Gene Ther. 2014;21:38–44. Thaci B, Ahmed AU, Ulasov IV, Wainwright DA, Nigam P, Auffinger B, Tobias AL, Han Y, Zhang L, Moon KS, Lesniak MS. Depletion of myeloid-derived suppressor cells during interleukin-12 immunogene therapy does not confer a survival advantage in experimental malignant glioma. Cancer Gene Ther. 2014;21:38–44.
12.
go back to reference Anna D, Edward V, Emma S, Sofia E. Intratumoral COX-2 inhibition enhances GM-CSF immunotherapy against established mouse GL261 brain tumors. Int J Cancer. 2014;134:2748–53.CrossRef Anna D, Edward V, Emma S, Sofia E. Intratumoral COX-2 inhibition enhances GM-CSF immunotherapy against established mouse GL261 brain tumors. Int J Cancer. 2014;134:2748–53.CrossRef
13.
go back to reference Bart T, Brown CE, Emanuela B, Katherine W, Prakash S, Sadhak S. Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy. Neuro-Oncology. 2014;16(10):1304–12.CrossRef Bart T, Brown CE, Emanuela B, Katherine W, Prakash S, Sadhak S. Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy. Neuro-Oncology. 2014;16(10):1304–12.CrossRef
14.
go back to reference Alexander S, Fabian W, Isabel T, Michael W. A disintegrin and metalloproteinases 10 and 17 modulate the immunogenicity of glioblastoma-initiating cells. Neuro-Oncology. 2014;16(3):382–91.CrossRef Alexander S, Fabian W, Isabel T, Michael W. A disintegrin and metalloproteinases 10 and 17 modulate the immunogenicity of glioblastoma-initiating cells. Neuro-Oncology. 2014;16(3):382–91.CrossRef
15.
go back to reference Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:480–9. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:480–9.
16.
go back to reference Kroesen M, Gielen P, Brok IC, Armandari I, Hoogerbrugge PM, Adema GJ. HDAC inhibitors and immunotherapy; a double edged sword. Oncotarget. 2014;5(16):6558–72.CrossRefPubMedPubMedCentral Kroesen M, Gielen P, Brok IC, Armandari I, Hoogerbrugge PM, Adema GJ. HDAC inhibitors and immunotherapy; a double edged sword. Oncotarget. 2014;5(16):6558–72.CrossRefPubMedPubMedCentral
Metadata
Title
New approaches for cancer immunotherapy
Authors
Ayfer Karlitepe
Ozgun Ozalp
Cigir Biray Avci
Publication date
01-06-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 6/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3491-2

Other articles of this Issue 6/2015

Tumor Biology 6/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine